The goal of this trial is to see whether a test based on a new technology which assesses tumor cell mass accumulation rate (MAR) can help to predict how patients with relapsed/refractory disease will respond to multiple myeloma treatments.
This trial is currently open and accepting patients.
Researchers are asking patients who participate in this clinical trial to provide an approximately 10mL (2 teaspoons) bone marrow sample. This sample will be collected at a time when a bone marrow biopsy is already being performed as part of your standard of care treatment and will not require an additional procedure. This study has two groups, also called cohorts. Each cohort will provide the same volume of a one-time bone marrow sample.
Researchers are also requesting access to your medical information and myeloma treatment history. This data will be de-identified, and securely stored.
If you agree to take part in this study, there will be no direct medical benefit or additional costs to you.
You and your physician will not be informed of the results of the tests on your tumor cells at the time your physician is deciding on your treatment as the accuracy of this test is not yet proven. Proving the value of this this test is the purpose of this study. The testingprocedure is not a treatment. There is no benefit to participating in this part of the study except for the satisfaction of contributing to scientific knowledge. We hope the information learned from this study will benefit other people with multiple myeloma in the future.
Enrollment: 130 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
October 23, 2019
Can you tell how well a myeloma treatment might work on your personal tumor by weighing the cancer cells? Clifford Reid, PhD and CEO of Travera shares a new approach to “personalized medicine” in multiple myeloma.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message